Big news: our prices just got a lot lower. Shop now|New here? Get up to $200 in welcome perks, valid for 14 days. Claim offer now
US shipping INCLUDED on orders above $200
Research Insights

All content and product details on this site are for educational purposes only. Products are for in-vitro studies (performed outside the body) and not FDA-approved for medical use. Any introduction into humans or animals is prohibited by law.

CJC-1295 Peptide Research: GHRH Analog and Growth Hormone

Nabiha Khalid
November 3, 2026
CJC-1295 Peptide Research: GHRH Analog and Growth Hormone

Brief Overview/Summary

Explore CJC-1295, a GHRH analog originally developed as an investigational compound. Studies have measured its effects on growth hormone and IGF-1 levels.

CJC-1295 is a synthetic peptide that functions as a modified version of growth hormone-releasing hormone (GHRH). Designed as a growth hormone secretagogue, this peptide represents a significant advancement in peptide research, featuring a unique 29-amino acid structure modified for stability

CJC-1295 & Its Characteristics

Modified GHRH analog

Numerous modifications have been made to growth hormone-releasing hormone (GHRH) to create analogs that retain some of the hormone's properties while removing others. Only the first 29 amino acids of GHRH make up one of such changes, CJC-1295. This GHRH analog, which is actually a maleimide derivative of hGRF(1-29), was developed to create a more soluble GH secretagogue that maintains the physiological effects of GHRH while being simpler to make in large numbers.

Development background

As a modified form of the first 29 amino acids of GHRH in metabolism, CJC-1295 shares chemical similarities with other GHRH analogs, such as Sermorelin; it is most similar to modified GRF (1-29), although the two peptides are not the same. The similarities between these peptides and the fact that CJC-1295 was initially made with an additional chemical compound known as the drug affinity complex (DAC) cause a lot of confusion [1].

Half-life characteristics

Studies have shown that CJC-1295 without DAC has a longer half-life of roughly 30 minutes because of its shortened 29-amino acid structure, which has four amino acids added to increase stability.

Peptide structural changes take place at particular locations with the goal of enhancing resistance to dipeptidyl peptidase-4 enzymatic degradation. These changes are:

  • Position 2: To possibly increase resistance to enzymatic degradation, L-alanine can be substituted with D-alanine.

  • Position 8: To lessen the possibility of asparagine rearrangement and amide hydrolysis, glutamine is substituted for asparagine.

  • Position 15: Glycine is replaced with alanine, which is thought to increase bioactivity.

  • Position 27: Leucine is substituted for methionine in order to perhaps stop methionine oxidation.

By decreasing enzymatic degradation and enhancing stability under physiological settings, these modifications in growth hormone levels seek to increase the peptide's robustness and functional activity. Additionally, it's thought that using DAC technology will increase the peptide's half-life to roughly 6–8 days.

Basic properties

It functions by raising the concentration of growth-related hormones in the blood. Elevated growth hormone has been discussed in relation to endpoints such as injury recovery, body composition, lean-mass and strength measurements, cognitive function, and sleep quality.

Mechanism of Action

The metabolic complex known as the DAC component is believed to further extend the peptide's half-life. The DAC's capacity to attach to plasma proteins is responsible for this extension. N-epsilon-3-maleimidopropionamide, a lysine derivative, is specifically attached to the C-terminus of CJC-1295 DAC as part of the DAC component. By combining this altered amino acid sequence with the DAC component, CJC-1295 DAC's pharmacokinetics may be supported, possibly increasing its half-life to about eight days. At the same time, it retains an elevated preference for GHRH receptors, comparable to that of CJC-1295 in the absence of DAC.

In modern studies, CJC-1295 without DAC is also relevant. For example, the synergistic potential of CJC-1295 and Ipamorelin has been investigated. It is hypothesized that this combination of GHRH analogs and peptides that appear to activate pituitary ghrelin receptors will cause somatotroph cells to produce a greater amount of GH. [3]

Research Evidence of CJC-1295 Peptide

In 2006, researchers looked into the impact of CJC-1295 DAC through two important clinical studies. One of four increasing concentrations of CJC-1295 DAC or a control chemical was used in the first research. In the second study, CJC-1295 DAC was exposed repeatedly at a single concentration.

The results showed that exposure to CJC-1295 DAC appeared to raise levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-I). It is thought that CJC-1295 DAC raises IGF-1 levels by inducing the generation of growth hormone, which may attach to liver cell receptors and initiate intracellular signaling pathways.

The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway may be triggered by this interaction, which would result in the transcription of the IGF-I gene. Following production, the IGF-I may be sent to different target tissues, where it may stimulate growth.

Investigation has demonstrated that CJC-1295 maintains normal GH release in animals lacking normal GHRH physiology [4]. Because of this, the peptide has been proposed as a subject of research on aberrant growth in humans and other mammalian species. Maintaining GH's regular pulsatile release is essential for the appropriate release of downstream hormones, placing CJC-1295 among important peptides for hormones like IGF-1 regulators and other endocrine modulators.

Research from the early 1990s examined CJC-1295 and other growth hormone-releasing factor (GRF) analogs in relation to ovulation in infertile female organisms. These models reportedly displayed "a significant increase of both follicular fluid IGF-I levels (compared to the previous cycle) and plasma GH levels immediately." [4] Insulin-like growth factor-1 (IGF-1) is thought to be necessary for ovulation, and growth hormone (GH) production and cycling probably have an impact as well.

Research conducted on animal models of superovulation has shown that around the time of ovulation, both GH and IGF-1 levels may rise noticeably. These results have been used to propose GH secretagogues, such as CJC-1295, as subjects of ovulation research.

Research Applications for CJC-1295 Peptide

Opportunities of CJC-1295 DAC were explored more thoroughly in murine models through further animal investigations. According to the findings of one investigation, regular administration of CJC-1295 DAC peptide was associated with normalized growth in the animal model studied.

According to the findings of the study, CJC-1295 DAC was examined for its effect on body composition, with endpoints including lean tissue and fat tissue measurements.

In GHRHKO mouse models, lean mass and subcutaneous fat mass measurements with CJC-1295 DAC exposure were reported to be consistent with control levels. This is in contrast to mice that did not get exposure, which reportedly exhibited elevated fat levels.

In addition, the researchers reported an increase in total pituitary RNA and GH mRNA, suggesting proliferation of somatotroph cells, which was supported by immunohistochemical images [4].

Future Research Perspectives

The synthetically produced peptide known as CJC-1295 was initially developed as an investigational compound.

According to the findings of one research investigation, CJC-1295 was associated with increases in serum growth hormone levels of between 200-1000%. Following these findings, CJC-1295 has been studied in older study populations and in research examining physical performance endpoints.

References

  1. Van Hout, M. C., & Hearne, E. (2016). Netnography of female use of the synthetic growth hormone CJC-1295: pulses and potions. Substance Use & Misuse, 51(1), 73-84.

  2. Henninge, J., Pepaj, M., Hullstein, I., & Hemmersbach, P. (2010). Identification of CJC‐1295, a growth‐hormone‐releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2(11‐12), 647-650.

  3. Sackmann-Sala, Lucila, Juan Ding, Lawrence A. Frohman, and John J. Kopchick. "Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects." Growth Hormone & IGF Research 19, no. 6 (2009): 471-477.

  4. Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294.

Read more about peptides